Verona Pharma Plc has appointed two new commercial officers to help it prepare for the possible launch of its lead product for chronic obstructive pulmonary disease. The company expects to make a regulatory submission in the US in the first half of 2023. Matthew Casbon has been named head of sales, marketing and training, while Matthew Rysavy is head of market access and trade. Mr Casbon was most recently chief business officer of Target RWE, an organisation that collects and analyses real world data. Prior to this, he was head of global strategic marketing at Circassia Group Plc, a respiratory pharmaceutical and device company.
Mr Rysavy comes from BioDelivery Sciences International Inc, a specialty pharma company, where he was head of market access and trade.
Verona Pharma announced the appointments on 24 August 2022.
Copyright 2022 Evernow Publishing Ltd